Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer
Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial presented at the ESMO 18th World Congress of Gastrointestinal Cancer.1

"Systemic treatment for hepatocellular carcinoma has long consisted of just one agent, sorafenib, which was shown to provide a significant improvement in life expectancy almost 10 years ago, but no other agent has surpassed its benefits," said Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer group at the Hospital Clínic in Spain and Scientific Director of the Network for Biomedical Research for Hepatic and Digestive Diseases (CIBEREHD), and principal investigator for the study.

This international, multicenter, phase 3 trial enrolled 573 patients with intermediate or advanced stage hepatocellular carcinoma, who had all been previously treated with sorafenib, and randomized them 2:1 to 160 mg oral regorafenib or placebo once daily for weeks 1 to 3 of each 4-week cycle, in addition to best supportive care.

After a median of 3.6 months of treatment, patients receiving regorafenib showed a 38% reduction in the risk of death and a 54% reduction in the risk of progression or death compared to placebo.

Patients had a mean progression-free survival of 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

Overall, 65.2% of patients in the regorafenib group showed complete or partial response or stable disease, compared to 36.1% in the placebo group.

The safety and side effect profile of regorafenib was similar to sorafenib, with hypertension, hand-foot skin reaction, fatigue, and diarrhea all being significantly more common in patients taking the drug.

The benefits of the drug are evident regardless of the cause or stage of the tumor, Bruix explained, but analysis of biomarkers would reveal whether there might be certain subgroups of patients likely to derive even greater benefit from this treatment.

"This is a very difficult to treat cancer but now we have an effective second-line agent, which is good news for the patients and also for the field as interest in further developments will be stimulated," Bruix said.

Reference

1. Bruix J, Merle P, Granito A, et al. Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial. Abstract LBA-03, Presentation at: ESMO 18th World Congress of Gastrointestinal Cancer; June 28-July 1, 2016; Barcelona, Spain.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs